Ionis Pharmaceuticals, Inc. (IONS): Price and Financial Metrics


Ionis Pharmaceuticals, Inc. (IONS)

Today's Latest Price: $59.09 USD

0.33 (-0.56%)

Updated Jan 27 6:55pm

Add IONS to Watchlist
Sign Up

Overall POWR Rating


POWR Components:

 Trade Grade  Buy & Hold Grade  Peer Grade  Industry Rank


Industry Rank:

Ranked of 215 in Medical - Pharmaceuticals

See all "A" rated Strong Buy stocks

IONS Stock Summary

  • The price/operating cash flow metric for Ionis Pharmaceuticals Inc is higher than 92.98% of stocks in our set with a positive cash flow.
  • IONS's price/sales ratio is 10.63; that's higher than the P/S ratio of 88.93% of US stocks.
  • Over the past twelve months, IONS has reported earnings growth of -3,436.9%, putting it ahead of just 0.51% of US stocks in our set.
  • Stocks with similar financial metrics, market capitalization, and price volatility to Ionis Pharmaceuticals Inc are CAPR, LSCC, AMPH, CDE, and INCY.
  • IONS's SEC filings can be seen here. And to visit Ionis Pharmaceuticals Inc's official web site, go to www.ionispharma.com.
IONS Daily Price Range
IONS 52-Week Price Range

IONS Stock Price Chart More Charts


IONS Price/Volume Stats

Current price $59.09 52-week high $86.58
Prev. close $59.42 52-week low $53.34
Day low $58.25 Volume 834,600
Day high $59.79 Avg. volume 945,765
50-day MA $61.68 Dividend yield N/A
200-day MA $64.04 Market Cap 8.31B

Ionis Pharmaceuticals, Inc. (IONS) Company Bio


Ionis Pharmaceuticals, Inc., a RNA-targeted drug discovery and development company, focuses on developing drugs for patients with severe and rare diseases. The company was formerly known as Isis Pharmaceuticals, Inc. and changed its name to Ionis Pharmaceuticals, Inc. in December 2015. Ionis Pharmaceuticals, Inc. was founded in 1989 and is based in Carlsbad, California.

IONS Price Forecast Based on DCF Valuation

Current PriceDCF Fair Value Target: Forecasted Gain:
$59.09$28.83 -51%

Below please find a table outlining a discounted cash flow forecast for IONS, in which we model out valuation assuming a variety of terminal growth rates. To summarize, we found that Ionis Pharmaceuticals Inc ranked in the 38st percentile in terms of potential gain offered. In terms of the factors that were most noteworthy in this DCF analysis for IONS, they are:

  • In the past 5.51 years, Ionis Pharmaceuticals Inc has a compound free cash flow growth rate of 0.29%; that's better than 73.22% of cash flow producing equities in the Healthcare sector, where it is classified.
  • The business' balance sheet suggests that 7% of the company's capital is sourced from debt; this is greater than only 21.56% of the free cash flow producing stocks we're observing.
  • Ionis Pharmaceuticals Inc's effective tax rate, as measured by taxes paid relative to net income, is at 318 -- greater than 99.43% of US stocks with positive free cash flow.


Terminal Growth Rate in Free Cash FlowReturn Relative to Current Share Price
0%-52%
1%-52%
2%-51%
3%-51%
4%-51%
5%-50%

Want more companies with a valuation profile/forecast similar to that of Ionis Pharmaceuticals Inc? See PBYI, GSK, CHE, NVS, and JNJ.





IONS Latest News Stream


Event/Time News Detail
Loading, please wait...

IONS Latest Social Stream


Loading social stream, please wait...

View Full IONS Social Stream

IONS Price Returns

1-mo -2.78%
3-mo 4.18%
6-mo -10.56%
1-year 3.74%
3-year 39.33%
5-year -15.42%
YTD -2.19%
2019 11.75%
2018 7.48%
2017 5.16%
2016 -22.77%
2015 0.31%

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!



Page generated in 0.7542 seconds.